0.1630+0.00 (+0%)
Oct 9, 9:35:27 AM EDT · OTC Markets OTCQB · RENXF · USD
Key Stats
Market Cap
93.89MP/E (TTM)
-Basic EPS (TTM)
-0.16Dividend Yield
0%Recent Filings
8-K
Renalytix reverts to FPI status
8-K
AGM resolutions all approved
Renalytix plc's shareholders overwhelmingly approved all resolutions at its December 19, 2024 AGM, including adoption of the 2024 annual report and ratification of auditors CohnReznick and PKF Littlejohn. Yet equity incentive and share issuance proposals passed with 84% support amid notable opposition. This bolsters board flexibility for talent retention and capital raising. All votes cleared decisively.
10-Q
Q1 FY2025 results
Renalytix posted Q1 FY2025 revenue of $522K, up 14% y/y from $459K, with gross profit flipping to $100K from a $43K loss as costs fell 16% to $422K—early signs of commercialization traction for kidneyintelX.dkd. Operating expenses plunged 53% to $4.2M, driven by 67% lower R&D ($921K) and 46% slimmer G&A ($3.3M), yielding a $4.1M operating loss, 54% narrower than last year's $8.9M. Diluted EPS improved to $(0.04) from $(0.11), matching basic shares of 105.7M as convertibles proved anti-dilutive. Cash dwindled to $909K from $4.7M, with operating burn at $3.8M (down 60% y/y) and no free cash flow disclosed; post-quarter, $14.9M equity raise and debt restructuring bolster liquidity, while $8.2M fair-valued convertible notes (5.5% rate, due 2029) loom. Net loss narrowed to $4.7M from $10.2M, but fair-value hits on notes widened the gap from operating loss. Expenses are shrinking fast.
8-K
EGM approvals enable fundraising
Renalytix plc's shareholders overwhelmingly approved all resolutions at the October 31, 2024 extraordinary general meeting, authorizing share allotments up to £171,915 in nominal value for non-EIS/VCT placing shares, £91,376 for conversion shares, £95,969 for subscription shares, and $7,880,744 for new convertible bonds, alongside disapplying pre-emption rights. This bolsters the company's capital-raising flexibility amid its turnaround efforts. Director Dan Levangie resigned the same day, without disagreement. Board gains new expertise.
8-K
Renalytix raises £11.8M, restructures debt
Renalytix plc announced a £11.8 million fundraise via placing and subscription of 131 million new ordinary shares at 9 pence each, a 12.5% premium to the prior close, while restructuring £8.7 million in convertible debt into equity and a new bond maturing 2029. The company terminated its Nasdaq listing, shifting ADSs to OTCQX for £1.9 million annual savings, and appointed Julian Baines as executive chairman. Proceeds target sales, marketing, and EHR integrations, slashing monthly burn to £560,000; yet Nasdaq delisting risks reduced visibility.
CMHSF
COMPREHENSIVE HEALTHCARE SYS IN
0.39+0.00
DH
Definitive Healthcare Corp.
2.77-0.17
FORA
Forian Inc.
2.33-0.02
HWAIF
HealWELL AI Inc.
1.04-0.02
NGHLF
Nightingale Health Oyj
1.75+0.00
PSNL
Personalis, Inc.
9.62+0.06
RMHI
Retrieve Medical Holdings Inc
1.30+0.00
RNXT
RenovoRx, Inc.
1.05-0.08
SOPH
SOPHiA GENETICS SA
4.54+0.45
TEM
Tempus AI, Inc.
88.84+2.25